Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy.
about
Molecular Biomarkers of Pancreatic Intraepithelial Neoplasia and Their Implications in Early Diagnosis and Therapeutic Intervention of Pancreatic CancerMolecular therapy of colorectal cancer: progress and future directionsCrystal and molecular structure of beta-cyclodextrins functionalized with the anti-inflammatory drug Etodolac.The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies.Celecoxib regulates apoptosis and autophagy via the PI3K/Akt signaling pathway in SGC-7901 gastric cancer cells.Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.Conjugates of cisplatin and cyclooxygenase inhibitors as potent antitumor agents overcoming cisplatin resistance.From COX-2 inhibitor nimesulide to potent anti-cancer agent: synthesis, in vitro, in vivo and pharmacokinetic evaluation.Stromal, rather than epithelial cyclooxygenase-2 (COX-2) expression is associated with overall survival of breast cancer patients.Characterization of the inflammatory microenvironment and identification of potential therapeutic targets in wilms tumorsThe role of chemoprevention by selective cyclooxygenase-2 inhibitors in colorectal cancer patients - a population-based study.Use of conventional and -omics based methods for health claims of dietary antioxidants: a critical overview.Metabolic syndrome and cancerConjugation of cisplatin analogues and cyclooxygenase inhibitors to overcome cisplatin resistance.Cancer chemopreventive ability of conjugated linolenic acids.A New Ligustrazine Derivative-Selective Cytotoxicity by Suppression of NF-κB/p65 and COX-2 Expression on Human Hepatoma Cells. Part 3Anti-inflammatory and antioxidative effects of six pentacyclic triterpenes isolated from the Mexican copal resin of Bursera copalliferaMorphogenesis of pancreatic cancer: role of pancreatic intraepithelial neoplasia (PanINs)Relationship between the expression of cyclooxygenase-2 and survivin in primary pterygium.Fluorocurcumins as cyclooxygenase-2 inhibitor: molecular docking, pharmacokinetics and tissue distribution in miceAssociation of osteopontin and cyclooxygenase-2 expression with breast cancer subtypes and their use as potential biomarkersSurgery as a double-edged sword: a clinically feasible approach to overcome the metastasis-promoting effects of surgery by blunting stress and prostaglandin responses.Improving cancer immunotherapy by targeting tumor-induced immune suppression.Anticancer property of bromelain with therapeutic potential in malignant peritoneal mesothelioma.Garcinol inhibits tumour cell proliferation, angiogenesis, cell cycle progression and induces apoptosis via NF-κB inhibition in oral cancer.Celecoxib increases EGF signaling in colon tumor associated fibroblasts, modulating EGFR expression and degradation.Ikappa B kinasebeta/nuclear factor-kappaB activation controls the development of liver metastasis by way of interleukin-6 expression.Suppression of cFLIP by lupeol, a dietary triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells.Nitric oxide-donating aspirin inhibits the growth of pancreatic cancer cells through redox-dependent signaling.Myeloid-derived suppressor cells in murine AIDS inhibit B-cell responses in part via soluble mediators including reactive oxygen and nitrogen species, and TGF-β.The TLR-2/TLR-6 agonist macrophage-activating lipopeptide-2 augments human NK cell cytotoxicity when PGE2 production by monocytes is inhibited by a COX-2 blocker.Genetics of pancreatic cancer and implications for therapy.Chemoprevention of DMH-induced rat colon carcinoma initiation by combination administration of piroxicam and C-phycocyanin.Cyclooxygenase as a target in chemoprevention by probiotics during 1,2-dimethylhydrazine induced colon carcinogenesis in rats.Comparison of NSAIDs activity in COX-2 expressing and non-expressing 2D and 3D pancreatic cancer cell cultures.Disruption of Chromosomal Architecture of cox2 Locus Sensitizes Lung Cancer Cells to RadiotherapyMetal-based anticancer agents: targeting androgen-dependent and androgen-independent prostate and COX-positive pancreatic cancer cells by phenanthrenequinone semicarbazone and its metal complexes
P2860
Q26765241-0B801C56-50EE-44FA-938C-7DFD77EF1CC3Q27005764-FB477663-C106-4BF2-81D8-C2112AE82F5DQ33430067-6808D83B-A88B-4E3E-A551-3E200150C897Q33737469-A1D7DBB3-F33E-45A7-ADFB-A9EE0855D522Q33747725-8FBD22D3-C84B-4C24-BB3A-68F45DF620B5Q33903025-E94BA0B1-1E20-4F5D-9F2F-7B4146DAF259Q34060461-29F6B53E-3F67-404C-8176-AA4973DE9462Q34084150-5BAC2467-A591-44F8-9838-A5EEB8A946F9Q34316720-17F0A7F8-5A5B-4E43-9A7C-756A552193E2Q34369331-3D596526-075B-43CD-8137-38ECF9BAFDEDQ34502963-0819C1D9-C9A0-4E15-B4DA-50D2970C30E1Q34781792-537550E6-F548-4473-A1C5-3CF512688561Q35319301-4595B31F-2F70-4A50-9B9B-D7DD04F16DAFQ35334366-57E96C9E-EF88-4FD6-B718-EB274A2D9374Q35600117-A936B39A-040F-4955-A542-F4DEA1E799BBQ35902645-20E90E7E-117C-4147-A531-4FCA72640BA3Q36175370-B345F2FF-20E9-4262-B87C-E2D4BC853B11Q37088011-4E2587A2-E94E-4612-B1CB-CA538A0A17BFQ37110100-3C0805FB-D681-402D-A7FB-AF8CFFBA1143Q37138897-6A696031-BCE4-45AE-802C-F0DD73905925Q37326197-24997048-B039-4421-A2BB-C710BCE545FEQ37342761-3830F868-ECDA-4386-BB13-8F38A1C2DA1DQ37830362-9AD4EE92-6772-451B-A18B-67F72C407690Q38097532-2FCA8032-8E65-4CE7-93A1-805E11BA2DA7Q38862175-E5389C57-7D1B-44B0-A85A-6236EC08841DQ38873392-A9CEB884-69E8-49A9-814C-1773C2A95F45Q39788628-09F07BD5-9CB1-4C63-93BA-A268F42A7360Q39889983-B84429A0-6C9D-468F-8E50-3DEC9F7F6FD6Q39937602-2900BD5B-82EC-47A4-9D51-E6C293291209Q40538846-7C08FA3E-2ABC-4A1B-A6CA-2F6E07871E5AQ40876421-72247487-8CE4-47EE-8DFE-FDE3E573F36EQ49606173-391EC048-ADF9-41E0-BA1D-6487F2D2B5A5Q53280521-4754E67D-28B2-4E01-9AAA-B2DC3C0D36B0Q54460901-FD889387-EE77-430E-9B50-3437722F8D39Q55379173-5803D082-83D4-4BEA-A8DB-B2035BDE2721Q57039796-0901BEB5-24A5-42A1-B2AD-8CC54FE5F79BQ58223669-7993B09B-C744-4C8B-83DE-23C0D1E4F38A
P2860
Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy.
@en
type
label
Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy.
@en
prefLabel
Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy.
@en
P2093
P1476
Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy.
@en
P2093
Fazlul H Sarkar
Shreelekha Adsule
Subhash Padhye
P304
P356
10.2174/138955707780859431
P577
2007-06-01T00:00:00Z